Magellan Gold Corporation Price, Forecast, Insider, Ratings, Fundamentals & Signals

Wallace, id / accesswire / january 16, 2024 / magellan gold corporation (otc pink:mage) ("magellan" or the "company"), is pleased to announce that the company has entered into an agreement with gold express mines, inc. for the purchase of three copper-focused properties, two of which are in idaho, and one in arizona. the copper cliff property, in adams county, idaho, is located about nine miles north of the town of cuprum, idaho.

Wallace, id / accesswire / january 8, 2024 / magellan gold corporation (otc pink:mage) ("magellan" or the "company"), is pleased to announce that the company has entered into a certain agreements with ajb capital investments llc ("abj") and gold express mines, inc. ("gem") pursuant to which ajb assigned to gem all of abj's right, title, obligation, liability and interest in that certain promissory note, dated february 2021 (the "promissory note"), issued by the company to ajb. the aggregate principal amount of the promissory note outstanding is $100,000.

San francisco--(business wire)--today, humble games, the publishing team of the beloved humble bundle brand, debuted the humble games showcase to a public audience, sharing insight into their slate for 2023 and beyond. during the showcase, the team doubled down on the company’s dedication to high-quality indie games that deliver approachable yet deeply original experiences for players worldwide. fans from around the world were treated to the reveals of six new titles, led by wizard of legend 2 from dead mage, which is now a humble games owned ip, and lost skies from bossa studios, one of the biggest and most ambitious indie titles from the publisher to date. in addition to this the team revealed new game updates from previously announced titles and a surprise game launch...

Cambridge, mass.--(business wire)--2seventy bio, inc. (nasdaq: tsvt), a leading immuno-oncology cell therapy company, today announced new data featuring novel approaches combining the company’s platform car t cell and t cell receptor technology and unique cell therapy engineering capabilities to potentially enhance treatment potency in a range of cancers. the data were shared in three presentations at this year’s american society of gene & cell therapy (asgct) annual meeting in los angeles, california. “we’re excited to present new data related to our programs in acute myeloid leukemia, non-hodgkin lymphoma and solid tumors,” said philip gregory, d.phil., chief scientific officer, 2seventy bio...

Dartmouth, nova scotia & cambridge, mass.--(business wire)--imv inc. (the “company” or “imv”) (nasdaq: imv; tsx: imv), a clinical-stage biopharmaceutical company developing a portfolio of immune-educating therapies based on its novel dpx® platform to treat solid and hematologic cancers, today announced that it was notified by the listing qualifications department of the nasdaq stock market llc ("nasdaq") that nasdaq, in accordance with nasdaq listing rules 5101, 5110(b) and im-5101-1, has in exercising its discretion determined to delist the company's common shares as a result of the company's announcement on may 1, 2023 that the nova scotia supreme court had issued an initial order (the “initial order”) granting the company and its subsidiaries protection under the companies’ creditors arrangement act (r...